New drug cocktail targets Hard-to-Treat lung cancer with liver metastases
NCT ID NCT07545213
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether combining SKB264 (a chemotherapy) with anlotinib (a targeted therapy) can shrink tumors and control disease in people with advanced non-small cell lung cancer that has spread to the liver and stopped responding to standard EGFR-targeted drugs. About 27 participants will receive both drugs in cycles, with frequent clinic visits. The study compares results to historical data to see if the combination works better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SKB264 (a chemotherapy drug) and anlotinib (a targeted therapy drug)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with advanced lung cancer that has spread to the liver and no longer responds to standard targeted therapy.
- What could go wrong
- This is a small, early-phase trial with only 27 participants and no control group. The combination may cause significant side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fourth Affiliated Hospital of Zhejiang University, School of Medicine
Yiwu, Zhejiang, 322000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?